Dengue Vaccines Market

How big is the Dengue Vaccines Market in 2026?

USD 97.5 million in 2026, reaching USD 216.3 million by 2036 at a 8.3% CAGR

The dengue vaccines market was valued at USD 90.0 million in 2025. The market is set to reach USD 97.5 million by 2026-end and grow at a CAGR of 8.3% between 2026-2036 to reach USD 216.3 million by 2036. Dengvaxia will dominate with a 47.8% share, while Paediatric will lead with a 53.7% share.

Dengue vaccine procurement is shaped by endemic country immunization programs, WHO prequalification timelines, and serotype-specific efficacy evidence. Demand reflects government procurement of licensed dengue vaccines for paediatric and adult populations in tropical and subtropical regions. Buyers include national immunization program managers, PAHO and UNICEF procurement agencies, and private travel medicine providers evaluating serotype coverage, age-group suitability, and cold chain requirements.

Growth reflects increasing dengue burden across endemic regions and expanding vaccine access through WHO prequalification and GAVI support. WHO reported in 2025 that dengue cases continued to rise globally, with over 5 million reported cases sustaining government investment in vaccination programs.

Buyers separate suppliers on serotype coverage, seroprevalence testing requirements, and regulatory approval breadth. Sanofi relies on its licensed Dengvaxia chimeric vaccine, while Takeda gains preference where TAK-003 (Qdenga) where pre-vaccination screening is not required for broader population immunization.

Key Takeaways of Dengue Vaccines Market

• Endemic country immunization programs are expected to sustain dengue vaccine procurement as dengue case burden increases.
• Dengvaxia is expected to account for 47.8% of product demand in 2026 because Sanofi's licensed vaccine maintains first-mover procurement position in seropositive populations.
• Paediatric is projected to hold 53.7% of age group demand in 2026 because children bear the highest dengue hospitalization burden in endemic countries.
• Government Procurement Programs is anticipated to represent 61.6% of distribution demand in 2026, supported by national immunization and PAHO/UNICEF bulk purchasing.
• Thailand leads with a 13.1% CAGR through 2036 as national dengue immunization program expansion sustains vaccine procurement.
• Sanofi is expected to compete through its licensed Dengvaxia position in seropositive population programs.

Analyst Perspective

"Buyers are expected to judge dengvaxia on performance and total cost of ownership rather than headline price. Dengue vaccine adoption is expected to depend on WHO prequalification timelines and national immunization program funding. Suppliers that demonstrate broad serotype coverage with simplified pre-vaccination requirements are likely to secure government procurement contracts. Market success is projected to depend on meeting cold chain logistics and serotype efficacy requirements across endemic country immunization programs."
- Anurag Sharma, Principal Consultant at Future Market Insights

Why is the Dengue Vaccines Market growing?

Rising Dengvaxia and Paediatric demand across healthcare end users

• Dengue-vaccine demand follows national immunization decisions and endemic-country disease burden rather than private-market purchasing.
• Thailand leads growth at 13.1% CAGR as national dengue immunization program expansion sustains vaccine procurement.
• Paediatric holds 53.7% of age group revenue, indicating where standardization is concentrating buyer spend.

Because public programs drive volume, dengue-vaccine spend concentrates with manufacturers whose serotype coverage and pre-vaccination screening fit national immunization and procurement requirements.

How is the Dengue Vaccines Market segmented?

The dengue vaccines industry is segmented by product, age group, end user, distribution channel, technology, and region.

The dengue vaccines market is segmented by product, age group, end user, distribution channel, technology, and region. By product, the market covers Dengvaxia, TAK-003 (Qdenga), and pipeline candidates. By age group, the market covers paediatric and adult. By end user, the market covers direct sales to governments and international organizations, and private healthcare. By distribution channel, the market covers government procurement programs and retail pharmacy. By technology, the market covers chimeric vaccine technology, live attenuated vaccine technology, and subunit and inactivated approaches. Regions include North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

How does dengvaxia shape demand within the product category?

Product selection determines clinical fit, workflow efficiency, and procurement priority across care settings. Dengvaxia anchors the category, keeping buyer spend concentrated where qualification and service support are already established. Demand concentrates here because Sanofi's licensed vaccine maintains first-mover procurement position for seropositive populations.

• Dengvaxia is expected to account for 47.8% of product demand in 2026 because Sanofi's licensed vaccine maintains first-mover procurement position for seropositive populations.
• Chimeric Vaccine Technology is projected to hold 45.5% of technology demand as Dengvaxia's yellow fever backbone chimeric platform remains the established commercial technology.

What supports paediatric age group demand?

Paediatric age group shapes buyer requirements because segment choice here determines clinical fit, workflow efficiency, and procurement priority across care settings. Demand concentrates here because children bear the highest dengue hospitalization burden in endemic countries.

• Paediatric is projected to hold 53.7% of age group demand in 2026 because children bear the highest dengue hospitalization burden in endemic countries.
• Direct Sales To Governments And International Organizations is forecast to represent 58.0% of end-user demand as national immunization programs drive the majority of vaccine procurement.

How do distribution channel and technology shape procurement?

Distribution channel and technology decide who controls the purchase and how the product reaches the account; together they determine clinical fit, workflow efficiency, and procurement priority across care settings. Demand concentrates here because national immunization and PAHO/UNICEF bulk purchasing dominate dengue vaccine procurement.

• Government Procurement Programs is expected to hold 61.6% of distribution demand because national immunization and PAHO/UNICEF bulk purchasing dominate dengue vaccine procurement.
• Live attenuated vaccine technology is gaining share as Takeda's TAK-003 Qdenga expands regulatory approvals without mandatory pre-vaccination screening.

What are the drivers, restraints, and opportunities in the Dengue Vaccines Market?

Near-term procurement is shaped by endemic country dengue burden, WHO prequalification, and serotype coverage evidence.

• Driver: Increasing dengue case burden and hospitalization rates in endemic countries are expected to push government vaccine procurement for national immunization programs.
• Restraint: Pre-vaccination seroprevalence screening requirements for Dengvaxia are likely to slow broad adoption if testing infrastructure limits population coverage.
• Opportunity: Continued GAVI co-financing and expansion of TAK-003 Qdenga's already-achieved WHO prequalification (obtained May 2024) is expected to broaden lower-income endemic country access.

Dengue burden is expected to increase vaccine procurement. WHO reported in 2025 that global dengue case counts continued to rise, with multiple endemic countries expanding immunization program budgets.

Seroprevalence screening requirements are expected to limit Dengvaxia adoption speed. PAHO reported in 2025 that pre-vaccination testing infrastructure remained a deployment barrier in several Latin American endemic countries.

WHO prequalification creates a practical route by enabling GAVI co-financing for endemic countries. Takeda reported in 2025 that its TAK-003 Qdenga vaccine progressed through WHO prequalification review for broader endemic country access.

Which country CAGRs are profiled in the Dengue Vaccines Market?

Thailand 13.1%, China 11.2%, India 10.3%, Indonesia 10.2%, UK 7.1% through 2036

Country	CAGR (2026 to 2036)
Thailand	13.1%
China	11.2%
India	10.3%
Indonesia	10.2%
UK	7.1%

Source: FMI's proprietary forecasting model and primary research. 5 of the countries covered in the full report are shown here as a representative subset.

How do country-level CAGRs compare in the Dengue Vaccines Market?

The country comparison spans 6.0 percentage points and reveals three distinct growth groups across the dengue vaccines market. Thailand and China form the upper tier with a 1.9-point difference, while India and Indonesia create a closely aligned middle group separated by only 0.1 percentage point. The United Kingdom remains at the lower end with a 3.1-point gap from Indonesia.

• Thailand leads the comparison at a 13.1% CAGR through 2036, supported by endemic disease burden, public immunization priorities and regional medical-hub investment, which support program-scale vaccine demand.
• China follows at an 11.2% CAGR, remaining 1.9 percentage points below Thailand. Endemic-region programs and regulatory review are shaping the pace of dengue-vaccine introduction.
• India records a 10.3% CAGR, creating a 0.9-percentage-point gap from China. Regulatory-review timelines and program design influence introduction pace, while local approval, endemic-region alignment and supply reliability remain important.
• Indonesia grows at a 10.2% CAGR, only 0.1 percentage point below India. Cold-chain reach and program-funding cycles can constrain rollout beyond priority districts, increasing the importance of supply readiness and program-aligned pricing.
• The United Kingdom records a 7.1% CAGR, remaining 3.1 percentage points below Indonesia. Travel-medicine demand and regulatory approval route dengue-vaccine access through structured public and private channels.

Comparable CAGRs can still produce different market conditions. Differences in endemic disease burden, regulatory timelines, immunization-program funding, cold-chain infrastructure, vaccine coverage requirements and healthcare access influence dengue-vaccine adoption across countries. The full report provides country-level CAGR analysis across major regions and individual markets within the dengue vaccines market.

Country-wise Analysis

• Thai demand for dengue vaccines is shaped by endemic disease priorities and public immunization programs. Travel-medicine positioning and approval breadth shape access. Manufacturers need approval clarity and screening guidance to serve travel and private channels.
• Chinese hospitals procure dengue vaccines through centralized purchasing programs that reward registered, competitively priced products. Demand draws on increasing dengue case burden and hospitalization rates in endemic countries. The Dengue Vaccines Market in China is projected to record an 11.2% CAGR during the assessment period, supported by tertiary hospital expansion and county-level facility upgrades. Cold-chain reach and program-funding cycles constrain rollout beyond priority districts. Manufacturers win with cold-chain-ready supply, program-aligned pricing, and serotype-coverage evidence.
• Indian providers buy dengue vaccines across expanding private hospital chains and cost-sensitive public tenders. Sales in India are forecast to expand at a 10.3% CAGR by 2036, supported by private hospital chain expansion and tertiary care investment. Regulatory-review timelines and program design govern introduction pace. Manufacturers need local approval, endemic-region program alignment, and supply reliability to convert demand.
• Indonesian demand for dengue vaccines scales with public health programs across a dispersed archipelago. The market outlook in Indonesia is anticipated to advance at a 10.2% CAGR over the assessment period, supported by a large endemic burden and expanding public health programs. Travel-medicine positioning and approval breadth shape access. Manufacturers need approval clarity and screening guidance to serve travel and private channels.
• UK providers procure dengue vaccines through NHS frameworks and structured tender cycles. Demand in the United Kingdom is forecast to rise at a 7.1% CAGR over the forecast period, supported by NHS procurement frameworks and structured tender demand. Cold-chain reach and program-funding cycles constrain rollout beyond priority districts. Manufacturers win with cold-chain-ready supply, program-aligned pricing, and serotype-coverage evidence.

Who are the notable companies in the Dengue Vaccines Market?

Sanofi, Takeda Pharmaceuticals, Emergex Vaccines, Indian Immunologicals Ltd., GSK, Merck, Codagenix, and Panacea Biotec are the notable companies shaping this market.

The field concentrates around vaccine manufacturers whose serotype coverage and screening requirements fit national immunization and travel-medicine channels. Global vaccine and pharmaceutical companies compete across Dengvaxia chimeric vaccine, TAK-003 Qdenga live attenuated and Vaccine R&D pipeline throughout established accounts. Dengue vaccine development specialists emphasize T-cell dengue candidate and Codon deoptimized candidate, while regional vaccine manufacturers serve regional demand through Indian vaccine manufacturing. A workable entry is an endemic-region manufacturing or next-generation candidate position. Growth depends on WHO prequalification, national-program alignment, and cold-chain reliability across each launch market. Breadth pays off through portfolios that pair serotype coverage with simplified pre-vaccination screening. A workable entry is an endemic-region manufacturing or next-generation candidate position. Growth depends on WHO prequalification, national-program alignment, and cold-chain reliability across each launch market. Breadth pays off through portfolios that pair serotype coverage with simplified pre-vaccination screening.

• Sanofi and Takeda Pharmaceuticals combine Dengvaxia chimeric vaccine and TAK-003 Qdenga live attenuated across multiple national markets. GSK adds Vaccine R&D pipeline through established account relationships. Their edge comes from licensed serotype coverage and program-aligned supply.
• Emergex Vaccines, Codagenix and Panacea Biotec follow focused routes across T-cell dengue candidate, Codon deoptimized candidate and Vaccine development. Their commercial edge comes from next-generation candidate and regional-manufacturing positions rather than one licensed product.
• Indian Immunologicals Ltd. provides regional coverage through Indian vaccine manufacturing. These firms compete on a focused endemic-market strengths, though reach trails the global vaccine majors.

Competitive Benchmarking: Dengue Vaccines Market

Company	Portfolio Relevance	Vaccine Focus	Account Access	Service Reach
Sanofi	High	Dengvaxia chimeric vaccine	Strong	Global
Takeda Pharmaceuticals	High	TAK-003 Qdenga live attenuated	Strong	Global
GSK	Medium	Vaccine R&D pipeline	Strong	Global
Merck	Medium	Vaccine portfolio	Strong	Global
Emergex Vaccines	Medium	T-cell dengue candidate	Moderate	Regional
Indian Immunologicals Ltd.	Medium	Indian vaccine manufacturing	Moderate	Regional
Codagenix	Medium	Codon deoptimized candidate	Moderate	Regional
Panacea Biotec	Medium	Vaccine development	Moderate	Regional

Source: Future Market Insights competitive analysis, 2026. Ratings reflect relative portfolio relevance, workflow or project fit, service capability, and geographic reach.

Key Developments in the Dengue Vaccines Market

• In May 2024, Takeda's TAK-003 (Qdenga) received WHO prequalification, becoming the second dengue vaccine (after Dengvaxia) to reach that status; by 2026, Qdenga has been approved in 43 countries with more than 32 million doses distributed.
• In 2025, Sanofi announced it would discontinue manufacturing of Dengvaxia due to low global demand, with distribution ending in September 2025 and remaining stock expiring by September 2026; the EU marketing authorization was formally withdrawn in October 2025.

Key Players in the Dengue Vaccines Market

Global vaccine and pharmaceutical companies

• Sanofi
• Takeda Pharmaceuticals
• GSK
• Merck

Dengue vaccine development specialists

• Emergex Vaccines
• Codagenix
• Panacea Biotec

Regional vaccine manufacturers

• Indian Immunologicals Ltd.

Dengue Vaccines Market: Report Scope

Coverage field	Report scope
Market breakdown	Product, age group, end user, distribution channel, technology, and region.
Market Definition	Dengue vaccines include chimeric, live attenuated, and subunit vaccine products for paediatric and adult immunization against dengue serotypes, procured through government immunization programs and private healthcare channels.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.
Countries Covered	Thailand, China, India, Indonesia, Brazil, United Kingdom, and France.
Key Companies Profiled	Sanofi, Takeda Pharmaceuticals, Emergex Vaccines, Indian Immunologicals Ltd., GSK, Merck, Codagenix, Panacea Biotec.
Forecast Period	2026 to 2036.
Approach	FMI used primary interviews, source validation, and proprietary demand modeling.

Source: Future Market Insights, analysis driven by proprietary forecasting models and primary research

Dengue Vaccines Market: Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, sourcing teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Future Market Insights (FMI) analysis

Market Segmentation Analysis

Dengue Vaccines Market Segmented by Product:

• Dengvaxia
  • Live Attenuated Dengue Vaccine
    • First Generation Dengue Prevention Solution
    • Targeted Seropositive Population Use
  • Pandemic Scale Immunization Product
    • Improved Disease Burden Reduction
    • Public Health Program Integration
• Qdenga
  • Tetravalent Dengue Vaccine
    • Broad Spectrum Dengue Protection
    • Improved Safety Profile
  • Next Generation Dengue Immunization
    • Expanded Age Group Coverage
    • Enhanced Global Adoption Potential

Dengue Vaccines Market Segmented by Age Group:

• Paediatric
  • Childhood Dengue Prevention Programs
    • Reduced Hospitalization Rates
    • Improved Pediatric Health Outcomes
  • School Based Immunization Initiatives
    • Enhanced Community Protection
    • Reduced Disease Transmission
• Adult
  • Adult Dengue Immunization Programs
    • Reduced Severe Dengue Risk
    • Improved Population Immunity
  • Travel Vaccination for Adults
    • Enhanced Protection for Endemic Travel
    • Improved Preventive Healthcare

Dengue Vaccines Market Segmented by End User:

• Direct Sales To Governments And International Organizations
  • National Immunization Programs
    • Large Scale Vaccine Procurement
    • Improved Public Health Coverage
  • International Health Agencies
    • Coordinated Disease Control Initiatives
    • Enhanced Vaccine Accessibility
• Hospitals
  • Inpatient Vaccination Programs
    • High Patient Throughput Administration
    • Improved Clinical Immunization Coverage
  • Public And Private Hospitals
    • Enhanced Disease Prevention Capability
    • Reliable Vaccine Distribution
• Travel Medicine Clinics
  • International Travel Vaccination Centers
    • Improved Traveler Protection
    • Destination Based Immunization Support
  • Pre Travel Consultation Clinics
    • Enhanced Disease Risk Management
    • Improved Patient Awareness
• NGOs
  • Community Health Campaigns
    • Improved Rural Vaccine Outreach
    • Enhanced Awareness Programs
  • Humanitarian Health Organizations
    • Disease Prevention In High Risk Regions
    • Improved Vaccination Access

Dengue Vaccines Market Segmented by Distribution Channel:

• Government Procurement Programs
  • National Immunization Supply Chains
    • Large Scale Vaccine Distribution
    • Improved Public Health Coverage
  • International Health Organization Procurement
    • Coordinated Global Vaccine Access
    • Enhanced Endemic Disease Control
• Hospital Procurement
  • Hospital Pharmacy Distribution Systems
    • Direct Clinical Vaccine Availability
    • Improved Patient Access
  • Private Healthcare Supply Chains
    • Enhanced Vaccination Service Delivery
• Retail And Pharmacy Channel
  • Private Pharmacy Vaccination Services
    • Improved Urban Accessibility
    • Convenient Outpatient Immunization
  • Travel Clinic Pharmacy Networks
    • Enhanced Pre Travel Protection
    • Improved Patient Convenience

Dengue Vaccines Market Segmented by Technology:

• Chimeric Vaccine Technology
  • Multi Serotype Protection Vaccines
    • Broad Spectrum Dengue Immunity
    • Improved Cross Protection Efficiency
  • Virus Vector Based Vaccines
    • Enhanced Immune System Targeting
    • Improved Clinical Efficacy
• Live Attenuated Vaccine Technology
  • Weakened Virus Strain Vaccines
    • Enhanced Immune Response Activation
    • Improved Long Term Protection
  • Recombinant Vaccine Platforms
    • Improved Safety Profile
    • Enhanced Scalable Production

Dengue Vaccines Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Health Organization. (2025). Global Dengue Surveillance and Case Burden Report.
• Pan American Health Organization. (2025). Dengue Vaccine Deployment and Pre-Vaccination Screening Assessment.
• Takeda Pharmaceuticals. (2025). TAK-003 Qdenga WHO Prequalification Progress Report.
• Thailand Department of Disease Control. (2025). National Dengue Immunization Program.
• GAVI The Vaccine Alliance. (2025). Dengue Vaccine Co-Financing Framework.
• Central Drugs Standard Control Organisation India. (2025). Dengue Vaccine Regulatory Pathway.
• National Medical Products Administration China. (2025). Vaccine Regulatory Assessment Standards.
• ANVISA Brazil. (2025). Dengue Vaccine Approval and Procurement Standards.
• Indonesia BPOM. (2025). Dengue Vaccine Regulatory and Deployment Framework.

This bibliography uses primary government and company sources.

This Report Answers

• What is the estimated 2026 value of the dengue vaccines market?
• What market value is projected by 2036?
• What CAGR is forecast from 2026 to 2036?
• Which product is expected to account for a notable 2026 share?
• Which countries are profiled for CAGR comparison?
• Which companies are notable in the competitive landscape?